The Relationship Between the Residual Renal Function and Osteoporosis Treatment
- Conditions
- Osteoporosis
- Interventions
- Drug: Bis, SERM Teriparatide, Denosumab
- Registration Number
- NCT02304887
- Lead Sponsor
- Toshihiko Kono
- Brief Summary
The relationship between osteoporosis drugs and kidney damage is unclear. In this study, we plan to reveal relationship between osteoporosis drugs and kidney damage.
- Detailed Description
Chronic kidney disease (CKD)- mineral and bone disorder (CKD-MBD) is one of the topic in osteoporosis treatment. As many osteoporotic patients are older, many patients are under the deterioration of the renal function. In addition, several drugs might have the potential for kidney damage. But the relationship between osteoporosis drugs and kidney damage is unclear.
The main objective of this study is to reveal relationship between osteoporosis drugs and kidney damage.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
- Osteoporosis patients
Exclusion Criteria
- eGFR < 15
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Bisphosphonate Bis, SERM Teriparatide, Denosumab - Selective estrogen receptor modulator Bis, SERM Teriparatide, Denosumab - Teriparatide Bis, SERM Teriparatide, Denosumab - Senosumab Bis, SERM Teriparatide, Denosumab -
- Primary Outcome Measures
Name Time Method Longitudinal renal function changes by osteoporotic treatment Up to 120 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Tomidahama Hospital
🇯🇵Yokkaichi, Mie, Japan